IACTA
Pharmaceuticals
IACTA Pharmaceuticals is an innovative ophthalmic company developing a portfolio of novel assets in large ocular markets, beginning with ocular pain and dry eye disease.
Synergies: Leveraging Epica to Develop and Commercialize Novel Treatments for Debilitating and Deadly Conditions
The advanced imaging of Epica presents an unparalleled opportunity for Iacta to develop devices and therapies that better target debilitating and deadly diseases. The new treatments that we are able to develop represent an aggregate market opportunity in excess of $100 billion.One initial area of focus is blindness, particularly age-related macular degeneration which afflicts over 200 million people globally.
Blindness Treatment
THE RATIONALE:
Compromised blood flow to the back of the eye is a significant contributing factor to AMD; improving blood flow with interventional devices will disrupt the disease process, and halt progression.
OPTiC System
Ophthalmic

Percutaneous

Transluminal

Catheter
PRIMARY MARKET
$5B
Late-stage dry AMD
 with Geographic Atrophy
Estimated annual cases of 
 ~1 million patients in the US
SECONDARY MARKET